Napredna pretraga

Pregled bibliografske jedinice broj: 887255

Glycophenotype of breast and prostate cancer stem cells treated with thieno[2, 3-b]pyridine anticancer compound


Mastelić, Angela; Čikeš Čulić, Vedrana; Režić Mužinić, Nikolina; Vuica-Ross, Milena; Barker, David; Leung, Euphemia Y; Reynisson Johannes; Markotić Anita
Glycophenotype of breast and prostate cancer stem cells treated with thieno[2, 3-b]pyridine anticancer compound // Drug Design Development and Therapy, 11 (2017), 759-769 doi:10.2147/DDDT.S121122 (međunarodna recenzija, članak, znanstveni)


Naslov
Glycophenotype of breast and prostate cancer stem cells treated with thieno[2, 3-b]pyridine anticancer compound

Autori
Mastelić, Angela ; Čikeš Čulić, Vedrana ; Režić Mužinić, Nikolina ; Vuica-Ross, Milena ; Barker, David ; Leung, Euphemia Y ; Reynisson Johannes ; Markotić Anita

Izvornik
Drug Design Development and Therapy (1177-8881) 11 (2017); 759-769

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
CD15s ; CD44+/CD24− ; GM3 ; breast ; cancer stem cells ; prostate

Sažetak
Tumor progression may be driven by a small subpopulation of cancer stem cells (CSCs characterized by CD44+/CD24- phenotype). We investigated the influence of a newly developed thienopyridine anticancer compound (3-amino-5- oxo-N-naphthyl-5, 6, 7, 8-tetrahydrothieno[2, 3- b]quinoline-2-carboxamide, 1) on the growth, survival and glycophenotype (CD15s and GM3 containing neuraminic acid substituted with acetyl residue, NeuAc) of breast and prostate cancer stem/progenitor-like cell population. MDA-MB-231 and Du-145 cells were incubated with compound 1 alone or in combination with paclitaxel. The cellular metabolic activity was determined by the 3-(4, 5-dimethylthiazolyl- 2)-2, 5-diphenyltetrazolium bromide (MTT) assay. The type of cell death induced by 48-h treatment was assessed using a combination of Annexin-V-FITC and propidium iodide staining. Flow cytometric analysis was performed to detect the percentage of CD44+/CD24- cells, and GM3 and CD15s positive CSCs, as well as the expression of GM3 and CD15s per one CSC, in both cell lines. Compound 1 produces a dose- and time-dependent cytotoxicity, mediated mainly by apoptosis in breast cancer cells, and slightly (2.3%) but statistically significant lowering breast CSC subpopulation. GM3 expression per one breast CSC was increased, and the percentage of prostate GM3+ CSC subpopulation was decreased in cells treated with compound 1 compared with non-treated cells. The percentage of CD15s+ CSCs was lower in both cell lines after treatment with compound 1. Considering that triple-negative breast cancers are characterized by an increased percentage of breast CSCs and knowing their association with an increased risk of metastasis and mortality, compound 1 is a potentially effective drug for triple-negative breast cancer treatment.

Izvorni jezik
Engleski

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • MEDLINE
  • Zoological Record Online


Citati